New Two-Target antibody for eczema tested in early trial
Disease control
Terminated
This early-stage trial tested a new drug called NM26-2198, a bispecific antibody that blocks two inflammatory signals (IL-4R and IL-31) involved in atopic dermatitis (eczema). The study included 126 healthy volunteers and patients with moderate-to-severe eczema, receiving either …
Phase: PHASE1 • Sponsor: Yellow Jersey Therapeutics AG • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC